Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380811 | 1.00 | CA12 (0.44) | CA12CA1CA2CA9CTSS | |
| SCHEMBL3611054 | 0.87 | CTSS (0.48) | CA12CA1CA2CA9CTSS | |
| SCHEMBL15107465 | 0.87 | CTSS (0.48) | CA12CA1CA2CA9CTSS | |
| SCHEMBL1826688 | 0.84 | CTSS (0.45) | CA12CA1CA2CA9CTSS | |
| SCHEMBL3379645 | 0.84 | CTSS (0.48) | CA12CA1CA2CA9CTSS | |
| SCHEMBL3379647 | 0.84 | CTSS (0.48) | CA12CA1CA2CA9CTSS | |
| SCHEMBL7279022 | 0.81 | MAPK1 (0.52) | CA12CA1CA2CA9CTSS | |
| SCHEMBL20439377 | 0.81 | CTSS (0.49) | CA12CA1CA2CA9CTSS | |
| SCHEMBL11596126 | 0.81 | CTSS (0.49) | CA12CA1CA2CA9CTSS | |
| SCHEMBL24674856 | 0.81 | CA12 (0.46) | CA12CA1CA2CA9CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989186-B1 | HYDANTOIN BASED KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7612212-B2 | 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | CA12 2999/4885CA1 807/4885CA2 3199/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | CA12 3654/4885CA1 3331/4885CA2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.